## Note
nid: 1497381612005
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Rituximab, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::21_Cetuximab_Panitumumab, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::23_Rituximab, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::23_Rituximab::Rituximab, #AK_Step1_v11::#OME_banner::Basic_Science::07_Immunology, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::02_Rituximab, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::03_Cetuximab,_Panitumumab, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Cetuximab,_Panitumumab, #AK_Step1_v11::#Pixorize::03_Pharm::11_Oncology::Rituximab, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::02_Rituximab,_cetuximab,_bevacizumab,_alemtuzumab,_trastuzumab::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::3-HighYield-temporary
markdown: false

### Text
<div>
  <b>Rituximab</b> and <b>Cetuximab</b> are {{c1::<b>Chimeric</b>}}
  monoclonal antibodies
</div>

### Extra
<i>This is notable because people who take chimeric biologics are
at risk of serum sickness</i>
<div><img src="paste-20216411062273.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-34286723923971.jpg"><img src=
"paste-34359738368003.jpg"><img src=
"paste-34398393073667.jpg"><img src="paste-34540126994435.jpg">

### Sketchy
<img src="paste-390537081257985.jpg" class="resizer"><img src=
"paste-87d74ac95a67d78e1a0443bd770c17f44240fcf8.png" class=
"resizer">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/immunology?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_6.png"></a>
</div>

### Additional Resources


### One by one

